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I remember as a neophyte academician in
the early 80’s the excitement and at times
heated discussion generated by nitric oxide
(NO). How could this toxic and relatively
unheard-of gas possibly be a regulatory
molecule? Even its discovery was the result
of a laboratory mistake (Furchgott, 1995).
As with any revolutionary idea, there were
both zealous aficionados, naysayers and
folks in between that “just wanted more
proof.” As a result, it took nearly 10 years
for this field to reach its log growth phase
(Figure 1A); the fact that the number of
yearly publications has now leveled off at
approximately 7000 per year is probably
more attributable to resource limitations
than to enthusiasm. The physiological rel-
evance of carbonmonoxide (CO) was real-
ized shortly after (Wu and Wang, 2005)
but again there was a similar lag between
discovery and acceptability as the scien-
tific community tried to separate toxicol-
ogy and pharmacology from physiology
(Figure 1B).
Hydrogen sulfide (H2S) was the third
gas to be elevated to signaling status, i.e., a
“gasotransmitter” (Wang, 2002). H2S has
the same toxic pedigree as NO and CO
(Guidotti, 2010) but it has not received the
degree of initial skepticism that accompa-
nied the latter two. As shown in Figure 1C,
following the initial demonstrations of
H2S signaling in the nervous and cardio-
vascular systems by Kimura’s group (Abe
and Kimura, 1996; Hosoki et al., 1997) the
lag-time for H2S to catch on in the scien-
tific community took about as long as the
time for these two seminal papers to circu-
late. Within 3 years the log phase of H2S
publications had begun, and it continues
to this day.
It is not surprising that H2S was
greeted with enthusiasm; gaseous signal-
ing molecules were no longer novel, the
implications of toxicity arising from excess
signal were obvious, and a precedent for
therapeutic potential (and profit) were
firmly established. Add to this the fact that
exogenous H2S appears to affect virtually
every physiological system, it has poten-
tially more biochemical diversity than the
other gases, journals are eager for reviews
(132 in 2011 and 93 as of the time of
this writing in 2012), and away we go.
The thought that the Emperor may not be
wearing any clothes, and may even have a
few warts, seems to be lost in the gala of
the parade to the publisher and the patent
office.
This is not to belittle the consider-
able potential of H2S research, there have
been momentous gains, and undoubtedly
more to come. Exogenous H2S affects vir-
tually every organ system and physiolog-
ical process to which it has been applied.
Many of the effects of H2S are sup-
ported by compounds that are thought to
inhibit or augment endogenous H2S pro-
duction (See reviews; Caliendo et al., 2010;
Kimura, 2010; Szabo, 2010; Olson, 2012b;
Wang, 2012). The most notable among
these are the cardiovascular system, where
H2S mediates systemic vasodilation and
pulmonary vasoconstriction, angiogene-
sis, oxygen sensing and is cardioprotec-
tive, the nervous system where H2S affects
neuronal signaling, contributes to involved
retinal function and may be involved in
degenerative diseases, and the gastroin-
testinal (GI) tract where it contributes to
signaling, insulin release, and metabolism.
H2S appears to be anti-inflammatory in
most tissues, although it may be inflam-
matory in some. Contrary to common
thought, H2S itself does not readily react
with reactive oxygen species (ROS) but
it does stimulate glutathione production
and augment reducing equivalents in the
central nervous system (Kimura et al.,
2010). Even novel signaling mechanisms
whereby H2S interacts with the reduced
(sulfhydration) or oxidized sulfur of cys-
teine to activate or inactivate proteins have
been described (Mustafa et al., 2009; Tao
et al., 2012). As well-illustrated in this
issue, it is also becoming increasingly evi-
dent that the many of the biological effects
of H2S are mediated directly through H2S
interactions with ion channels (see also;
Tang et al., 2010; Munaron et al., 2012;
Peers et al., 2012).
Sulfide salts, such as NaHS and Na2S,
have been historically used to rapidly
generate H2S but this occurs at an
uncontrolled rate and their purity may
be problematic. These salts are gradu-
ally being replaced by the next gener-
ation of compounds that slowly release
H2S. The clinical applicability these true
H2S “releasing” drugs is now becom-
ing evident and they offer additional
advantages in that they can be com-
bined with other, unrelated drugs and pro-
vide a multi-focal therapeutic approach
(Caliendo et al., 2010; Olson, 2011;
Kashfi and Olson, 2012). Already, H2S-
releasing drugs have been combined with
a variety of compounds including virtu-
ally all non-steroidal anti-inflammatory
drugs (NSAIDs), sildenafil, levodopa, the
anti-glaucoma drug lantanoprost, and the
angiotensin-1 receptor antagonist losartan
to name a few. The ability of some of these
H2S-releasing drugs to uniquely counter
the adverse effects of aspirin and other
NSAIDs on the GI tract or to treat other
inflammatory process such as inflamma-
tory bowel disease (IBD), irritable bowel
syndrome (IBS) and acute and chronic
joint pain are nearing or already in initial
clinical trials. A third generation of com-
pounds that can be combined with drugs
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FIGURE 1 | Frequency histogram of the number of yearly publications on
(A) nitric oxide (NO), (B) carbon monoxide (CO) and (C) hydrogen sulfide
H2S. Vertical lines indicate approximate year of the first description of a
biological effect of the gas. Approximately 10 years passed before NO and
CO caught on as biologically relevant signal molecules, acceptance of H2S
was much quicker.
such as NSAIDs and release both H2S and
NO, the so-called “NOSH” compounds
may further increase potency and versatil-
ity; preliminary studies suggest they may
be especially effective in the treatment of
cancer (Kashfi and Olson, 2012).
A better understanding of H2S bio-
chemistry and metabolism has also lead to
promising therapy (Viscomi et al., 2010;
Drousiotou et al., 2011). Ethylmalonic
encephalopathy (EE) is an autosomal
recessive deletion in the ETHE1 gene that
encodes a mitochondrial sulfur dioxyge-
nase. EE is typically fatal in the first
decade of life. Patients with EE present
with greatly elevated urinary and tissue
thiosulfate concentrations and increased
tissue H2S, presumably due to the inabil-
ity of cells to efficiently metabolize H2S.
This condition has recently been treated
by oral administration of the bactericide
metronidazole, to inhibit H2S production
by colonic bacteria, and N-acetylcysteine.
The latter acts as a membrane-permeable
precursor of reduced glutathione (GSH)
and appears to combine with H2S to form
a non-toxic persulfide, GSSH. Targeting
another mitochondrial enzyme, sulfur
quinone oxidoreductase (SQR), which cat-
alyzes the first step in H2S oxidation, may
be a future therapeutic option (Linden
et al., 2010).
The intent of this opinion is not to
be a nayser, but just to request more
proof that while we are going full-speed
ahead we are also going in the right
direction and not out of control. Clearly,
we don’t need proof that exogenous H2S
activates/inhibits numerous biological sys-
tems, or that these systems can be mod-
ulated by fiddling with H2S metabolism,
or that H2S has specific molecular targets,
there are at least 225 reviews to substanti-
ate these. However, we do need to critically
examine a number of practical and techni-
cal issues. These include the promiscuity of
many “selective” inhibitors of H2S biosyn-
thesis, separating physiological from phar-
macological effects of H2S, dosing issues,
and measuring H2S in tissues and blood.
Obviously, all are related; I will focus on
the latter two.
H2S is a gas and we need some justifi-
cation for ignoring its ephemeral nature;
the half-life of H2S in open containers is a
few scant minutes, even less when aerated
(DeLeon et al., 2011). When we expose
cells and tissues to H2S for hours and
days in tissue culture or organ baths what
are we looking at? Is this why we need
to expose tissues to excessive H2S concen-
trations that can’t possibly exist naturally?
And where do we separate physiology from
toxicology?
More importantly, however, we really
need proof that what we are measuring
in tissues and blood is actually H2S. This
has profound implications in perhaps the
most exciting avenue of H2S research,
its therapeutic potential. My biggest con-
cern is that if we do not do this right it
can have disastrous consequences result-
ing in missed diagnoses and inappropriate
therapies. I will give three examples, one
where a simple calculation can be used
to tell us if tissue H2S values are realistic,
a second that will (hopefully) red-flag
plasma and blood H2S measurements and
a third that serves as an excellent exam-
ple of how critical thinking can put the
brake on a potentially dangerous clinical
application.
First, lets look at tissue H2S concen-
trations. Most studies report tissue H2S
concentrations anywhere from 1 nmol/mg
protein to up to values well in excess
of 10µmol/mg protein. As I have pre-
viously calculated (Olson, 2012a) if one
assumes a cell is 15% protein and 70%
water then 1µmol H2S/mg protein would
result in a cytosolic concentration of
214mmol/l! Even 1 nmol/mg protein in
a cell is still be more than five times
the toxic level. How can these values
be so high? There are at least two rea-
sons. First, most methods require incubat-
ing the tissue for 30min or more under
anoxic conditions. These conditions pre-
vent normal H2S oxidation while H2S pro-
duction continues unabated. Second, the
most commonly used methods, methy-
lene blue, monobromobimane and ion-
selective electrodes (ISE) measure more
than just H2S; and it’s generally not clear
what many of these other molecules are
(Olson, 2012a). The alkaline antioxident
buffer used with the ISE generates H2S
from cysteine in serum albumin (Whitfield
et al., 2008).
Even more troubling are H2S mea-
surements in plasma and blood. H2S is
commonly measured in plasma using the
above methods or in headspace gas (typi-
cally after equilibration for 30min ormore
Frontiers in Physiology | Membrane Physiology and Biophysics January 2013 | Volume 4 | Article 2 | 2
Olson H2S potential and precaution
under anoxic conditions) and concen-
trations from 1–30µmol/l are common,
although some go as high as 300µmol/l.
These are unrealistic because of the rea-
sons described above, and as so ele-
gantly shown by Furne et al. (2008), the
human nose can detect 1µmol/l; blood
obviously doesn’t smell like rotten eggs.
While these erroneous values are a detrac-
tion in laboratory experiments, they are
potentially dangerous when used diagnos-
tically. And the latter is becoming more
common. I offer a simple challenge to
any laboratory that is interested in, or
currently measuring H2S in blood; in
addition to making your standard curve
in buffer, make another standard curve
in whole blood and compare the two.
I guarantee the values obtained in the
plasma will not correlate with buffer val-
ues and, in fact, there will be no measur-
able H2S in the former because red blood
cells avidly remove H2S (Whitfield et al.,
2008).
There is considerable, and alarming
interest in using blood H2S measurements
for clinical diagnosis and a variety of
pathological conditions have been corre-
lated with altered plasma H2S. Here I will
give a single example. Goslar et al. (2011)
used the standard methylene blue method
to measure total plasma sulfide in patients
admitted to the intensive care unit (ICU)
with various forms of shock. Presuming
plasma pH is 7.4 this would be ∼20%
H2S gas; in acidosis the percent H2S gas
will increase. Goslar et al. (2011) reported
that plasma sulfide was lower in survivors
than non-survivors (13 vs. 32µM) and
they concluded that plasma sulfide could
be used as a predictor of mortality in the
ICU. This concept was critically tested in
a rat model of hemorrhagic shock by Van
de Louw and Haouzi (2012) who found
no evidence for such a correlation and, in
fact, the methylene blue method measured
plasma turbidity, not sulfide.
This Opinion is not meant to discour-
age research in this exciting field but to
encourage critical thinking about how we
are generating information and interpret-
ing it. Clearly, these are exciting times.
However, it may be necessary now and
then to apply the brakes on exuberance to
keep things from getting out of control.
These points are further detailed in several
recent reviews (Olson, 2009, 2011, 2012a;
Linden et al., 2010).
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